Who are Eris Lifesciences's main competitors?

Named competitors: Mankind Pharma (MANKIND.NS), Torrent Pharma (TORNTPHARM.NS), Alkem Laboratories (ALKEM.NS). The cockpit's measured peer set (industry) also includes Tsumura & (4540.T), PharmaResearch (214450.KS), Guobang Pharma (605507.SS), China National Accord Medicines (000028.SZ), Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ), Pfizer (PFIZER.NS).

How has Eris Lifesciences stock performed?

Over six months to 6 Nov 2026 the shares returned -10.8% against -9.3% for the median peer; over one year -23.8%.

← CockpitCompetitor Analysis › ERIS.NS Eris LifesciencesOpen in the cockpit ↗

Eris LifesciencesERIS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Domestic-focused branded generics company selling diabetes, cardiac and dermatology drugs to Indian doctors and patients.

≈ A domestic-only Indian branded generics makerMomentum neutral 46

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$1.82B

US dollars, full cap

Free float

32%

of shares outstanding

$/day

$1.42M

20-day average traded

Fwd P/E

25.7×

forward earnings

ROIC−WACC

-1.5 pp

WACC 11.9%

Hurdle

+4 pp

Req g minus delivered

Next earnings

77 days

22 Jan 2027

Close · INR₹1,234

1D+0.3%

1W+6.7%

1M+7.7%

3M-10.8%

6M-10.8%

YTD-18.0%

1Y-23.8%

ATR %3.1%

Beta0.55

52w lowhigh29.1% off high

What Eris Lifesciences does

Domestic-focused branded generics company selling diabetes, cardiac and dermatology drugs to Indian doctors and patients.

Sells prescription brands in India that doctors recommend and pharmacies stock, so revenue relies on field sales teams building prescribing habits in long-term therapy areas such as diabetes and heart disease, and on buying brands from other companies. Founder Amit Bakshi leads the company.

In one line: A domestic-only Indian branded generics maker.

Products and services

Diabetes/cardiac brands
Dermatology products
Nephrology/CNS drugs

Customers

Doctors/hospitals in India
Retail pharmacies

Where it sits in the supply chain

Formulation R&D
Manufacturing
Domestic branded generics distribution

What could go right

Domestic chronic disease drug growth
In-licensing/M&A of brands

What could go wrong

Fully domestic revenue concentration
Government price controls

Moat: narrow (brand, distribution). Strong doctor-relationship-driven brand building in chronic therapy areas within India.

Headquarters: Ahmedabad, India · Founded: 2007 · Employees: 3,076

Named competitors

Mankind Pharma MANKIND.NS
Torrent Pharma TORNTPHARM.NS
Alkem Laboratories ALKEM.NS

Eris Lifesciences at a glance

Size Eris Lifesciences (ERIS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.82B, the 391st largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,234 on 6 Nov 2026.

Performance Over six months the shares fell 10.8%, against -9.3% for the median peer and 0.0% for the India market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 11.1% over the last twelve months (peer median +10.7%); the operating margin is 26.3% (peer median 12.2%).

Valuation It trades at 25.7× forward earnings against a peer median of 22.0× (6th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.5 points below its cost of capital (11.9% WACC).

Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Eris Lifesciences against the median of its 20 peers (local-currency closes).

Eris Lifesciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	₹33.3B	₹31.3B	₹28.9B	₹20.1B	₹16.9B
Revenue growth	—	+8%	+44%	+19%	—
Gross profit	₹15.9B	₹14.3B	₹13.0B	₹10.1B	₹8.54B
EBITDA	₹11.6B	₹11.3B	₹10.3B	₹7.01B	₹5.47B
Net income	₹7.08B	₹6.20B	₹3.52B	₹3.92B	₹3.82B
Free cash flow	n/a	₹542M	₹7.73B	₹2.87B	-₹5.69B
Capital expenditure	n/a	₹2.97B	₹1.55B	₹1.29B	₹8.41B
Total debt	₹24.3B	₹23.6B	₹24.8B	₹27.8B	₹8.77B

Quarterly statements and history in the cockpit →

Eris Lifesciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Eris Lifesciences is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Eris Lifesciences is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Eris Lifesciences is the large dot.

Eris Lifesciences competitors and peer comparison

Head to head with its named competitors (ERIS.NS vs MANKIND.NS vs TORNTPHARM.NS vs ALKEM.NS)
Company	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g
Eris Lifesciences ERIS.NS	$1.82B	-11%	+11%	26%	25.7×	24.7%
Mankind Pharma MANKIND.NS	$11.1B	+7%	+13%	21%	43.2×	27.6%
Torrent Pharmaceuticals TORNTPHARM.NS	$19.1B	+9%	+42%	22%	72.2×	37.9%
Alkem Laboratories ALKEM.NS	$6.67B	-5%	+13%	17%	27.4×	24.3%

How Eris Lifesciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Eris Lifesciences against its 20 peers (data as of 6 Nov 2026)
Measure	ERIS.NS	Peer median	Rank in peer set
1-month return	+7.7%	-1.0%	5th highest of 21
6-month return	-10.8%	-9.3%	9th lowest of 21
Distance from 52-week high	-29.1%	-27.8%	10th lowest of 21
Revenue growth (TTM)	+11.1%	+10.7%	10th highest of 20
Operating margin	26.3%	12.2%	7th highest of 20
Forward P/E	25.7×	22.0×	6th most expensive of 17
Growth the price implies (Req g, 7 yrs)	24.7%	6.0%	2nd most demanding of 14
Growth delivered (Del g)	+20.9%	+9.9%	5th highest of 14
Hurdle (Req g minus delivered)	+3.9 pp	-6.9 pp	6th most demanding of 14
ROIC minus cost of capital	-1.5 pp	+1.4 pp	8th lowest of 20
EV / EBITDA	16.7×	15.1×	5th most expensive of 10
Net debt / EBITDA	1.9×	-1.0×	3rd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Eris Lifesciences ERIS.NS	India	$1.82B	-11%	+11%	26%	25.7×	24.7%	+20.9%
Tsumura & 4540.T	Japan	$1.81B	+2%	+10%	18%	10.1×	n/a	n/a
PharmaResearch 214450.KS	South Korea	$1.79B	-25%	+34%	39%	12.4×	-14.2%	+37.6%
Guobang Pharma 605507.SS	China	$1.84B	-8%	+3%	12%	15.9×	-5.8%	+7.4%
China National Accord Medicines 000028.SZ	China	$1.85B	-4%	0%	2%	11.1×	-9.4%	+4.2%
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ	China	$1.77B	-11%	+7%	39%	27.8×	19.5%	+10.8%
Pfizer PFIZER.NS	India	$1.87B	-19%	+12%	34%	21.5×	11.2%	+2.4%
Beijing Aosaikang Pharmaceutical 002755.SZ	China	$1.76B	-25%	-13%	12%	63.3×	14.7%	-14.0%
Agios Pharmaceuticals AGIO	United States	$1.76B	+6%	+141%	-467%	n/a	n/a	n/a
Cohance Lifesciences COHANCE.NS	India	$1.75B	-11%	+41%	6%	82.6×	n/a	n/a
Shenzhen Hepalink Pharmaceutical 002399.SZ	China	$1.88B	-13%	-6%	8%	22.5×	0.1%	+0.5%
Sarepta Therapeutics SRPT	United States	$1.88B	-11%	-20%	-3%	n/a	11.9%	+32.4%
Maze Therapeutics MAZE	United States	$1.90B	+29%	+700%	-728%	n/a	n/a	n/a
Shenyang Xingqi Pharmaceutical 300573.SZ	China	$1.91B	-25%	+17%	33%	13.7×	6.0%	+29.1%
Yifan Pharmaceutical 002019.SZ	China	$1.72B	-14%	-5%	8%	27.8×	n/a	n/a
Caplin Point Laboratories CAPLIPOINT.NS	India	$1.92B	+28%	+15%	31%	24.6×	29.3%	+15.7%
Alivus Life Sciences ALIVUS.NS	India	$1.92B	+32%	+8%	31%	24.4×	20.4%	+6.2%
Harmony Biosciences HRMY	United States	$1.93B	+7%	+20%	22%	8.6×	-10.9%	+40.3%
Faes Farma FAE.MC	Spain	$1.71B	+5%	+32%	14%	17.1×	3.1%	+9.9%
OneSource Specialty Pharma ONESOURCE.NS	India	$1.94B	-12%	+11%	6%	45.0×	n/a	n/a
SELLAS Life Sciences SLS	United States	$1.70B	+68%	n/a	n/a	n/a	n/a	n/a

Questions

Who are Eris Lifesciences's main competitors?: Named competitors: Mankind Pharma (MANKIND.NS), Torrent Pharma (TORNTPHARM.NS), Alkem Laboratories (ALKEM.NS). The cockpit's measured peer set (industry) also includes Tsumura & (4540.T), PharmaResearch (214450.KS), Guobang Pharma (605507.SS), China National Accord Medicines (000028.SZ), Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ), Pfizer (PFIZER.NS).
Is Eris Lifesciences expensive compared with its peers?: On forward p/e it trades at 25.7× against a peer median of 22.0×, 6th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Eris Lifesciences stock performed?: Over six months to 6 Nov 2026 the shares returned -10.8% against -9.3% for the median peer; over one year -23.8%.